Where women currently are left out of 88% of clinical trials (even those specific to female disorders), we are working to shift the outlook of women’s non-reproductive health worldwide. To do so, we are targeting several key vulnerabilities within the medical cycle: by accelerating the acquisition of data to key research areas; by snowballing IP to expand understanding of women’s health as it relates to the dynamic hormonal cycle; and by licensing IP to lower the barrier to entry for researchers and FemTech startups alike. 